Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020
CHI Insight Pharma Reports
July 1, 2011 214 Pages - SKU: CHI6576836
|
|
By 2020, the current renaissance of biotechnology will have resulted in a broad range of products that will, almost without exception, involve a degree of protein engineering. This report discusses new developments in therapeutic protein engineering and developments that are likely to occur through 2020. Contents include:
- State of the current technology and where the immediate development vectors are pointing
- Current efforts to engineer developability into protein drug candidates
- How major regulatory agencies might address engineered proteins
- 60 company profiles providing a cross-section of the corporate protein engineering environment in 2011
- Directions the protein engineering business is likely to take in the context of technical, strategic, and financial terms
- How globalization in the protein engineering and design field may imply sharper competition but also increased transnational cooperation
|
- Executive Summary
- Chapter 1
INTRODUCTION
- 1.1. From Esoteric Basic Science to the Bioengineered Protein Drug
- Structure as the Key to Protein Form and Function
- Antibodies: Immune Proteins Naturally Designed For Combinatorial Diversity
- 1.2. Leaving the Hype Cycle Legacy Behind
- Why the Markets Overestimated Biotech in the 1980s
- Biologicals as the Fastest-Growing Pharma Market Segment
- Chapter 2
PERSPECTIVES AND CHALLENGES IN BIOLOGICS DISCOVERY AND DESIGN
- 2.1. Types of Protein Drugs
- Hormones, Cytokines, and Enzymes
- Antibodies and Their Fab Fragments
- 2.2. Characterizing Targets with “Protein Druggability”
- Affinity vs. Avidity
- 2.3. The Technologies
- Display Technologies: Phages and Yeast
- 2.4. Engineering “Developability” Into Therapeutic Proteins
- Combinatorial Mutagenesis and Directed Evolution
- Rational Design: Bioinformatics and Modeling For In Silico Immunology
- Synthetic Gene Design and Optimization
- Modifying Glycosylation and Other Critical Post-Translational Modifications
- 2.5. Antibody Derivatives and Biobetters
- Toolboxes for Immunoglobulin Design and Engineering
- 2.6. New Developments in Display Technologies and Screening Strategies
- The Changing Concept of the “Antibody Library”
- New Developments in Display Technologies
- Antibody Selection and Optimization beyond Cell Display Technologies
- Chapter 3
BUSINESS WITH PROTEIN ENGINEERING
- 3.1. The Protein Engineering Company: A Breed of its Own
- 3.2. Development and Financing Profiles for Protein Drugs
- The Lengthening Timeline
- Risk and Capital Investment
- Product Pricing and Competition by Small-Molecule Drugs: Pharmacoeconomics is Key
- Engineering Proteins to Marketing Strategy
- Patenting Strategies for Engineered Proteins
- Protein Engineering to Avoid Manufacturing Issues
- 3.3. The Biosimilars Are Coming—the Biobetters Will Follow
- The Distinctive Complexity of Biologicals
- Comparables, Not Generics: Strategic Dilemma and Potential
- The FDA’s Long and Unfinished Way to Biosimilars
- Biosimilar Introduction and Market Penetration: Will Europe and Asia Set a Pattern for the United States?
- Targets for Biosimilars and Companies Developing Them
- 3.4. Biobetters: Engineering beyond Biosimilars
- Chapter 4
PERSPECTIVES FOR PROTEIN ENGINEERING
- 4.1. Recent Patenting Reveals Current Earliest-Stage R&D Patterns
- 4.2. The Evolution of the Protein Engineering Tools
- In Silico Immunology and Immunological Bioinformatics
- Synthetic Biology
- Protein Characterization Tools: The “Orthogonal Approach”
- 4.3. Alternative Expression Systems
- Beyond Today’s Bioreactors: Plants and Insects
- Unconventional Microbial Expression Systems
- Human Cell Lines
- 4.4. Biotech Drugs for “Undruggable” Pathways: A Realistic Option?
- 4.5. Engineering Proteins for Delivery Devices
- 4.6. Evolution of Regulatory Guidelines and Practices
- 4.7. Perspectives for Financing: Market-Tailored Strategies Are Needed
- Have an Eye on the Regions: Protein Engineering is Globalizing
- Chapter 5
COMPANIES IN THE PROTEIN ENGINEERING BUSINESS
- 5.1. Examples of Developer Companies in the Protein Engineering Business
- 4-Antibody AG
- Abbott Bioresearch Center, Inc.
- Ablynx NV
- Adimab, Inc.
- Affimed Therapeutics AG
- Affitech A/S
- Alexion Pharmaceuticals, Inc.
- Amunix, Inc.
- Apeiron Biologics AG
- Apexigen, Inc.
- Applied Integrin Science, Inc.
- Avipep Pty Ltd.
- BioInvent International AB
- Biogen Idec
- Biotecnol SA
- BioTransformations Ltd.
- Complix NV
- Corimmun GmbH
- Covagen AG
- Crescendo Biologics Ltd.
- Dyax Corp.
- Emergent BioSolutions, Inc.
- Fabrus LLC
- f-star GmbH
- Genmab A/S
- Glythera Ltd.
- ImmunGene, Inc.
- ImmunoGen, Inc.
- Immunomedics, Inc.
- ioGenetics, LLC
- Ixo Therapeutics Ltd.
- Kymab Ltd.
- MacroGenics, Inc.
- MedImmune
- Merus B.V.
- Micromet, Inc.
- Molecular Templates, Inc.
- MorphoSys AG
- NovImmune SA
- Pieris AG
- Perseid Therapeutics, LLC
- PharmAbcine
- Roche Glycart AG
- Seattle Genetics, Inc.
- SpectraMab GmbH
- Sutro Biopharma, Inc.
- Trion Pharma AG
- Trellis BioScience
- Viventia Biotechnologies, Inc.
- X-BODY Biosciences
- Xencor, Inc.
- XOMA (US), LLC
- Zyngenia, Inc.
- 5.2. The “Toolbox” Companies: Technology Vendors for Protein Engineering
- Accelrys, Inc.
- Attana AB
- Bioceros B.V.
- DNA2.0, Inc.
- Novozymes Biopharma US, Inc.
- Selexis, Inc.
- Zymeworks, Inc.
- References
- Company Index with Web Addresses
Share this report
Other tasks Related Markets Research & Development Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
